Tanvex BioPharma Inc (6541) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.058x

Based on the latest financial reports, Tanvex BioPharma Inc (6541) has a cash flow conversion efficiency ratio of -0.058x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-309.37 Million ≈ $-9.75 Million USD) by net assets (NT$5.36 Billion ≈ $169.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Tanvex BioPharma Inc (6541) market capitalisation for the company's overall valuation and market capitalisation.

Tanvex BioPharma Inc - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Tanvex BioPharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Tanvex BioPharma Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tanvex BioPharma Inc ranked by their cash flow conversion efficiency. See 6541 debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Saha-Union Public Company Limited BK:SUC	0.010x
Tata Steel (Thailand) Public Company Limited BK:TSTH	0.049x
Deutsche Real Estate AG F:DRE2	0.004x
Zippy Technology Corp TW:2420	0.059x
Sygnia Ltd JSE:SYG	0.363x
Ledesma SAAI BA:LEDE	0.123x
Orvana Minerals Corp. TO:ORV	0.525x
Sam Yung Tradi KO:002810	0.002x

Annual Cash Flow Conversion Efficiency for Tanvex BioPharma Inc (2013–2025)

The table below shows the annual cash flow conversion efficiency of Tanvex BioPharma Inc from 2013 to 2025. View 6541 stock price and chart for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$5.69 Billion ≈ $179.39 Million	NT$-1.01 Billion ≈ $-31.68 Million	-0.177x	+86.29%
2024-12-31	NT$893.31 Million ≈ $28.14 Million	NT$-1.15 Billion ≈ $-36.25 Million	-1.288x	+26.24%
2023-12-31	NT$821.11 Million ≈ $25.87 Million	NT$-1.43 Billion ≈ $-45.17 Million	-1.746x	-82.16%
2022-12-31	NT$1.39 Billion ≈ $43.84 Million	NT$-1.33 Billion ≈ $-42.02 Million	-0.959x	-93.15%
2021-12-31	NT$2.79 Billion ≈ $88.05 Million	NT$-1.39 Billion ≈ $-43.70 Million	-0.496x	+27.24%
2020-12-31	NT$2.62 Billion ≈ $82.57 Million	NT$-1.79 Billion ≈ $-56.32 Million	-0.682x	-8.89%
2019-12-31	NT$3.03 Billion ≈ $95.49 Million	NT$-1.90 Billion ≈ $-59.82 Million	-0.626x	-64.42%
2018-12-31	NT$4.21 Billion ≈ $132.79 Million	NT$-1.61 Billion ≈ $-50.59 Million	-0.381x	-17.86%
2017-12-31	NT$3.75 Billion ≈ $118.12 Million	NT$-1.21 Billion ≈ $-38.19 Million	-0.323x	-38.59%
2016-12-31	NT$3.57 Billion ≈ $112.57 Million	NT$-833.43 Million ≈ $-26.26 Million	-0.233x	+50.64%
2015-12-31	NT$1.45 Billion ≈ $45.62 Million	NT$-684.20 Million ≈ $-21.56 Million	-0.473x	+35.83%
2014-12-31	NT$589.64 Million ≈ $18.58 Million	NT$-434.17 Million ≈ $-13.68 Million	-0.736x	-23.91%
2013-12-31	NT$403.64 Million ≈ $12.72 Million	NT$-239.86 Million ≈ $-7.56 Million	-0.594x	--

About Tanvex BioPharma Inc

TW:6541 Taiwan Biotechnology

Market Cap

$257.13 Million

NT$8.16 Billion TWD

Market Cap Rank

#15635 Global

#698 in Taiwan

Share Price

NT$30.80

Change (1 day)

+0.82%

52-Week Range

NT$30.30 - NT$65.30

All Time High

NT$287.73